bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions - bluebird bio, Inc.
Zynteglo: Gene Therapy for Beta-thalassemia • BioPharma Media
Bluebird bio's gene therapy Zynteglo could have high price tag defense in beta thalassemia - Pharmaceutical Technology
ICER Draft Evidence Report on Bluebird Gene Therapy Zynteglo Finds It Provides Value at $2.1 Million - Global Genes
FDA Approves $2.8 million Gene Tx - Zynteglo - Anton Health
At $2.8 Million, Beti-cel Is a Canary in the Drug Cost Coal Mine
FDA Approves Bluebird's $2.8 Million Gene Therapy for Rare Blood Disease - WSJ
bluebird bio gets CHMP nod for gene therapy Zynteglo | Pharmaphorum
Potential blockbusters make a splash on market entry - Clarivate
blue-ex992_54.htm
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business Wire
bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype
Bluebird bio sets €1.6M price tag for rare blood disease gene therapy | S&P Global Market Intelligence
bluebird bio's Zynteglo gene therapy receives FDA approval
ICER's Favorable Assessment Of Bluebird Bio's Gene Therapy Zynteglo May Have Important Pricing And Reimbursement Implications
FDA approves bluebird bio's Zynteglo gene therapy for beta thalassemia; shares up 7% | Seeking Alpha
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
NICE turns down bluebird bio's gene therapy Zynteglo - PMLiVE
Bluebird wins U.S. approval for gene therapy for beta thalassemia - STAT
Bluebird Bio CEO defends $1.8 million price tag for new gene therapy
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies - Pharmaceutical Technology
Patient group echoes bluebird bio stance over Zynteglo UK funding snub
Bluebird puts €1.57m price on gene therapy Zynteglo - PMLiVE
NEW | Bluebirdbio Releases Resources For Patients On Gene Therapy Zynteglo® – TIF
Bluebird bio announces 1st commercial launch of ZYNTEGLO™in Germany – TIF
